Dynavax Technologies (DVAX) Rating Lowered to Neutral at JPMorgan Chase & Co.

Dynavax Technologies (NASDAQ:DVAX) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research note issued on Wednesday, Marketbeat Ratings reports. They presently have a $25.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $31.00. JPMorgan Chase & Co.’s target price would suggest a potential upside of 48.81% from the company’s current price.

Several other equities research analysts also recently weighed in on DVAX. BidaskClub raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Cantor Fitzgerald increased their price objective on shares of Dynavax Technologies from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Thursday, November 9th. Finally, Cowen reissued a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $24.83.

Shares of Dynavax Technologies (DVAX) traded down $0.40 on Wednesday, reaching $16.80. 1,340,000 shares of the company traded hands, compared to its average volume of 1,480,000. Dynavax Technologies has a 1 year low of $3.90 and a 1 year high of $24.45. The stock has a market cap of $1,020.00, a P/E ratio of -8.57 and a beta of 1.08.

In other Dynavax Technologies news, VP David Louis Johnson sold 3,092 shares of the stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now directly owns 7,780 shares of the company’s stock, valued at approximately $144,708. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Robert Coffman sold 7,500 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.

Large investors have recently made changes to their positions in the business. Cornerstone Capital Management Holdings LLC. acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $611,000. Paloma Partners Management Co acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $331,000. Bain Capital Public Equity Management LLC acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $4,657,000. Deutsche Bank AG boosted its holdings in shares of Dynavax Technologies by 2.4% in the 4th quarter. Deutsche Bank AG now owns 1,426,918 shares of the biopharmaceutical company’s stock valued at $26,682,000 after buying an additional 33,390 shares in the last quarter. Finally, Clearbridge LLC acquired a new position in shares of Dynavax Technologies in the 4th quarter valued at $10,335,000. 68.60% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Dynavax Technologies (DVAX) Rating Lowered to Neutral at JPMorgan Chase & Co.” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/14/dynavax-technologies-dvax-rating-lowered-to-neutral-at-jpmorgan-chase-co.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply